Table: Kubota Pharmaceutical Holdings -Q1 group results (IFRS)
May 14 (Reuters)-
Kubota Pharmaceutical Holdings Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2024 Mar 31, 2023 Dec 31, 2024
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 5 mln 5 mln
(-2.8 pct)
Operating loss 337 mln loss 445 mln
Pretax loss 343 mln loss 444 mln
Net loss 343 mln loss 444 mln
EPS Basic loss 6.10 yen loss 8.09 yen
EPS Diluted loss 6.10 yen loss 8.09 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Kubota Pharmaceutical Holdings Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4596.T
Recent news on Kubota Pharmaceutical Holdings
See all newsTable: Kubota Pharmaceutical Holdings 6-MTH group results (IFRS)
Table: Kubota Pharmaceutical Holdings -Q1 group results (IFRS)
Brief: Kubota Vision Signs Supply & Licensing Agreement With Laboratoires Kôl
Table: Kubota Pharmaceutical Holdings -2025 parent results
Table: Kubota Pharmaceutical Holdings -2025 group results (IFRS)